Verve Therapeutics, Inc.

NASDAQ:VERV

5.46 (USD) • At close April 29, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 13.086.8656.6925.6955.1443.1172.0931.4041.0120.9290000000000
Cost of Revenue 01.7541.6671.6321.5173.1993.0262.7592.5531.9971.1481.0130.9691.7570.3570.2940000
Gross Profit 13.085.1115.0254.0633.627-0.082-0.933-1.355-1.541-1.068-1.148-1.013-0.969-1.757-0.357-0.2940000
Gross Profit Ratio 10.7450.7510.7130.705-0.026-0.446-0.965-1.523-1.150000000000
Reseach & Development Expenses 55.04849.93850.98448.37646.81143.76547.2647.1137.28435.19733.12524.4925.93917.49513.42311.34515.5767.6185.6546.523
General & Administrative Expenses 14.09913.83714.54714.16312.28111.68613.41612.55311.4389.5929.0677.4356.6016.0073.5412.7162.0241.3541.0320.846
Selling & Marketing Expenses 00-1.667-1.632-1.517000000000000000
SG&A 14.09913.83712.8812.53110.76411.68613.41612.55311.4389.5929.0677.4356.6016.0073.5412.7162.0241.3541.0320.846
Other Expenses 001.6710.078-0.7130.802-0.6620.7382.177-3.3060.9381.6771.1390.7-36.0060.778-5.929-0.055-0.9441.689
Operating Expenses 69.14763.77563.86460.90757.57555.45160.67659.66348.72244.78942.19231.92532.5423.50216.96414.06117.68.9726.6867.369
Operating Income -56.067-56.91-58.839-56.844-53.948-52.334-58.583-58.259-47.71-43.86-42.192-31.925-32.54-23.502-16.964-14.061-17.6-8.972-6.686-7.369
Operating Income Ratio -4.286-8.29-8.792-9.981-10.488-16.79-27.99-41.495-47.144-47.2120000000000
Total Other Income Expenses Net 6.1056.8819.18.2145.6286.6434.7766.2846.678-1.331.2461.7591.2030.753-36.0010.798-5.931-0.018-0.8941.766
Income Before Tax -49.962-50.029-49.739-48.63-48.32-45.691-53.807-51.975-41.032-45.19-40.946-30.166-31.337-22.749-52.965-13.263-23.531-8.99-7.58-5.603
Income Before Tax Ratio -3.82-7.288-7.433-8.539-9.393-14.659-25.708-37.019-40.545-48.6440000000000
Income Tax Expense 0.0730.1040.0660.1060.032-0.0670.176-6.2840.0531.33-1.246-1.759-1.203-0.75336.001-0.7985.9330.0180.894-1.766
Net Income -50.035-50.133-49.805-48.736-48.352-45.758-53.983-45.691-41.085-46.52-39.7-28.407-31.337-22.749-52.965-13.263-23.531-8.99-7.58-5.603
Net Income Ratio -3.825-7.303-7.442-8.558-9.4-14.68-25.792-32.543-40.598-50.0750000000000
EPS -0.58-0.6-0.59-0.59-0.69-0.72-0.87-0.74-0.67-0.81-0.82-0.58-0.65-0.47-1.1-0.3-0.81-0.31-0.26-0.19
EPS Diluted -0.58-0.59-0.59-0.59-0.69-0.72-0.87-0.74-0.67-0.81-0.82-0.58-0.65-0.47-1.1-0.3-0.81-0.31-0.26-0.19
EBITDA -54.367-55.156-57.172-55.212-52.431-50.86-57.246-57.132-46.785-43.143-41.544-31.411-32.068-23.09-16.607-13.767-17.347-8.348-6.4-7.204
EBITDA Ratio -4.156-8.034-8.543-9.695-10.193-16.317-27.351-40.692-46.23-46.440000000000